Since the nationwide launch of the renewed national centralized drug procurement results, GoeGoe Honglin Pharm. has strictly fulfilled the responsibilities as a selected enterprise, with a focus on ensuring supply and safeguarding quality. With our reliable supply capacity and consistent product quality, we have gained wide recognition from medical institutions and the industry.

GoeGoe Honglin Pharm.'s successfully bid products—JUPOPINE^® Nifedipine Controlled-release Tablets, RoToFier^® Glipizide Extended Release Tablets, JUPOSHU^® Amlodipine Besylate Tablets, and JUPOPHON^® Ibuprofen Sustained-release Capsules—have all officially passed consistency evaluation. They are consistent with the Reference Listed Drug (RLD) in quality and efficacy, with mature clinical applications and well-proven therapeutic effects.

To fully guarantee clinical drug availability, GoeGoe Honglin Pharm. has maintained a steady and continuous supply by optimizing production planning and strengthening supply chain management. Adhering to the principle of quality first, we implement full-process quality control for all selected products and strictly follows GMP standards in production, ensuring that every batch of pharmaceuticals is safe, effective and consistently reliable.

With our dependable product quality and stable supply capacity, GoeGoe Honglin Pharm. upholds the corporate spirit of “Seeking Truth from Facts and Serving Society” through concrete actions. GoeGoe Honglin Pharm. remains committed to protecting public health and providing patients with long-term, safe and high-quality pharmaceutical solutions.